AI-Designed 'Multibody' Drug Advances in Autoimmune Disease Fight

WASHINGTON and NESS ZIONA, Israel – March 25, 2026 – A novel, AI-designed therapy for complex autoimmune diseases has cleared a significant preclinical hurdle, signaling growing confidence in the power of artificial intelligence to create smarter medicines. Biolojic Design, a biotech firm at the forefront of computational antibody engineering, announced it has earned a milestone payment from pharmaceutical giant Teva Pharmaceutical Industries Ltd. for the advancement of TEV ‘325.

The therapy, a first-of-its-kind 'multibody' antibody, is being developed for TH2-driven inflammatory conditions such as asthma and atopic dermatitis. The milestone payment from Teva, which holds the exclusive global license for the drug, validates the continued progress of TEV ‘325 as it moves through preclinical development, with a target of initiating human clinical trials in 2027.

This development not only marks a crucial step for the partnership but also highlights a major shift in drug discovery, where AI-driven platforms are beginning to solve complex biological problems that have long challenged traditional pharmaceutical research.

The Science of an Intelligent Antibody

At the heart of this advancement is Biolojic Design’s proprietary “multibody” technology. TEV ‘325 is not a conventional antibody. Unlike standard monoclonal antibodies that bind to a single target, or even more complex bispecific antibodies with fixed binding sites, this multibody is engineered for dynamic, adaptive action.

Each arm of the TEV ‘325 molecule was computationally designed to flexibly bind to one of two key inflammatory drivers: interleukin-13 (IL-13) or thymic stromal lymphopoietin (TSLP). These two cytokines are known to play critical roles in autoimmune conditions, but their prevalence can fluctuate at different stages of the disease or vary significantly between patients. Current therapies often target just one of these pathways, which may explain why they are only effective in about half of the patient population.

Biolojic's AI platform overcomes this limitation by creating a therapeutic that can essentially read and respond to the patient's unique inflammatory state in real-time. If TSLP is the dominant driver at a given moment, TEV ‘325 can engage it; if IL-13 levels are higher, the multibody can shift its focus. This adaptability is designed to provide a more personalized and potentially more effective treatment. Furthermore, the multibody is built on a natural human IgG antibody format, which is intended to maintain the safety, stability, and manufacturing advantages of traditional antibody therapies.

A Strategic Bet on Next-Generation Therapeutics

The collaboration represents a key element of Teva's “Pivot to Growth” strategy, which emphasizes innovation and partnerships to build a robust pipeline of novel medicines. By securing exclusive global rights to develop, manufacture, and commercialize TEV ‘325, Teva is making a significant investment in a next-generation therapeutic platform.

This move reflects a broader industry trend where large pharmaceutical companies are increasingly turning to agile biotech innovators to access cutting-edge science. The market for autoimmune and inflammatory diseases is highly competitive, with blockbuster drugs like Dupixent (which inhibits both IL-4 and IL-13 signaling) and Tezspire (a TSLP inhibitor) already established. For Teva, the unique adaptive mechanism of TEV ‘325 offers a powerful point of differentiation and the potential to capture a patient population that does not respond adequately to existing treatments.

The milestone payment underscores Teva’s continued commitment to the program as it progresses toward the clinic. Such partnerships are typically structured with upfront payments followed by substantial milestone payments tied to development, regulatory, and commercial achievements, along with royalties on future sales, aligning the interests of both the innovator and the developer for the long term.

New Hope for Patients with Chronic Conditions

For millions of people living with chronic inflammatory diseases like severe asthma and atopic dermatitis (eczema), the advancement of TEV ‘325 offers a new horizon of hope. These conditions are characterized by debilitating symptoms, including difficulty breathing and severe skin inflammation, which significantly impact quality of life. A major challenge in treating these diseases is their inherent variability.

The biological drivers of inflammation are not static. The ability of TEV ‘325 to adapt to a patient’s changing disease state could lead to more consistent and durable responses, potentially improving outcomes for those who have failed multiple lines of therapy. This approach embodies the promise of personalized medicine, moving beyond a one-size-fits-all strategy to a treatment that can tailor its activity to the individual.

By simultaneously addressing two validated disease pathways in a flexible manner, TEV ‘325 could provide a more comprehensive blockade of the inflammatory cascade. This could translate to better symptom control, fewer flare-ups, and a reduced burden of disease for patients grappling with these relentless conditions.

Validating the AI-Design Revolution

The progress of TEV ‘325 serves as powerful validation for Biolojic Design’s AI-powered platform. The company has previously demonstrated the platform’s success with AU-007, an AI-designed antibody for solid tumors that is currently in Phase 2 clinical trials, which the company claims was the first of its kind to enter the clinic. The continued advancement of its pipeline reinforces the company's position as a leader in the computational design of intelligent medicines.

“TEV ‘325 is our first multibody in development for autoimmune disease and, if it progresses, could become the second multibody and third AI-designed molecule from our platform to enter clinical trials,” said Yanay Ofran, PhD, CEO and founder of Biolojic Design, in a press statement. “This reflects Biolojic’s leadership position at the forefront of the AI-design revolution. These assets illustrate how AI can solve clinical problems that other technologies have been struggling with for years.”

As TEV ‘325 continues its journey through the rigorous stages of drug development, it represents more than just a single product candidate. It stands as a testament to a new paradigm in medicine, where artificial intelligence and human biology converge to create therapies that are not only powerful but also programmable and intelligent. This progression marks a significant step in a long-term strategy, with all eyes now on the path toward the targeted 2027 initiation of human clinical trials.